Navigation Links
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
Date:7/30/2008

A and protein product sequences, specific antibodies, and gene inhibition across different pathologies.

The Phase II prospective, randomized, multi-center, dose ranging study is designed to evaluate the efficacy and safety of PF-04523655 versus laser therapy in 160 patients with DME. Eligible patients will be randomized to receive intravitreal injections of one of three dose levels of PF-04523655 or laser. Therapeutic effect will be evaluated through visual acuity and retina morphological examinations conducted over a 36-month follow up period.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA locally and systemically to organs including the eye, ear, kidney, lung, spinal cord and bone marrow.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly available information, Quark believes this was the first siRNA delivered systemically in a human clinical trial. The Company has structure related technology licenses from Silence Therapeutics and from Alnylam.

In addition, Quark has a broad pipeline of siRNA drug candidates based a novel structure developed internally. The Company expects to utilize the structure to develop add
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
2. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
3. Quark Pharmaceuticals Appoints New Chief Medical Officer
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
8. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 This BCC Research report discusses the medical device ... growth and size, and opportunities for different devices and regions. ... Patent analysis in the report focuses on technological trends in ... Europe and Japan . ... the global medical device technologies market. - Analyze market structure, ...
(Date:9/18/2014)...  Iliad Neurosciences, Inc., a company focused on the ... Spectrum Disorders (ASD) announced today that it has entered ... for The State University of New York. ... to identify an abnormality in folate transport to the ... expected to be available for research use by physicians ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... MADISON, N.J., Jan. 6, 2012 Quest Diagnostics Incorporated ... of diagnostic testing, information and services, announced today the ... Health System to acquire S.E.D. Medical Laboratories. Under the ... assets of S.E.D. Medical Laboratories and will manage in-patient ...
... 2012 In preparation for meetings starting Monday, ... scheduled for 10:00 a.m. Thursday, January 12 at ... Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... the fourth quarter 2011:       -Approximately 935-950 ...
Cached Medicine Technology:Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories 2Questcor Pharmaceuticals Reports Strong Finish to 2011 2Questcor Pharmaceuticals Reports Strong Finish to 2011 3Questcor Pharmaceuticals Reports Strong Finish to 2011 4Questcor Pharmaceuticals Reports Strong Finish to 2011 5Questcor Pharmaceuticals Reports Strong Finish to 2011 6
(Date:9/18/2014)... Georgia (PRWEB) September 18, 2014 Technology ... the winners of its 2nd TAG Social Savvy Awards ... Junior Achievement’s Chick-fil-A Foundation Discovery Center in Downtown Atlanta. ... media. , Turner Sports was honored with the ... This year’s event also recognized innovators in 6 other ...
(Date:9/18/2014)... Researchers are trying to learn more about a condition ... in young athletes. In people with sickle cell ... muscle breakdown that can lead to kidney damage and ... players in the United States collapsed and died during ... trait. "More student-athletes with sickle cell trait have ...
(Date:9/18/2014)... NC (PRWEB) September 18, 2014 October ... also Domestic Violence Awareness Month. And the Centers for ... tells a scary story. , According to the CDC ... fourth of men in the U.S. experience some form ... intimate relationship. The same survey shows that about half ...
(Date:9/18/2014)... September 18, 2014 Fall is here, and ... bike is here to stay. Just as the temperature ... up, says Bikesdirect.com . Women across America are discovering ... calls a city bike. , Windsor Bicycles USA says, "City ... are higher than the typical road bike, and the seat ...
(Date:9/18/2014)... technology has shed new light on how certain symptoms ... according to a new study. PTSD is ... range of debilitating symptoms, such as flashbacks to a ... and avoiding certain situation and people, according to background ... opioid receptor in the brain linked to emotion that ...
Breaking Medicine News(10 mins):Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3Health News:Scientists Studying Sickle Cell Trait 2Health News:What you should know about domestic violence 2Health News:What you should know about domestic violence 3Health News:What you should know about domestic violence 4Health News:What you should know about domestic violence 5Health News:City Bikes Become a Must-have for Women This Fall, Says Bikesdirect.com 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 2Health News:Research Shows Possible Neurological Patterns for PTSD Symptoms 3
... WASHINGTON, DC) The Society for Cardiovascular Angiography and ... announced today that they will hold a unified interventional ... meeting will be known as The SCAI Annual Scientific ... be held concomitantly with the ACC Annual Scientific Session. ...
... men who have sex with men (MSM) in New York City, ... among MSM under age 30 have increased by 33% during the ... to almost 500 in 2006. New diagnoses have doubled among MSM ... under-30 group now accounts for 44% of all new diagnoses among ...
... Sept. 11 The Department of,Public Welfare today ... system whose personal information may have been contained,on ... office building in Harrisburg., The burglary remains ... the information on the stolen computers has been ...
... PT. RICHMOND, Calif., Sept. 11 Transcept,Pharmaceuticals, Inc., ... from proven CNS drugs, today announced,that Glenn A. ... present at the UBS 2007 Global Life Sciences ... Tuesday, September 25, 2007 at 4:00 p.m. ET. ...
... Is the Most Comprehensive Ever, NEW YORK, ... research,-- the most comprehensive ever conducted -- once ... safe, even among its heaviest users. The ... Use,Levels, Regulations, and Toxicological and Epidemiological Studies,",published in ...
... opportunities for immigrants to obtain legal residency and citizenship ... access to health care, according to an article published ... Affairs. , Immigrants now make up 12 percent ... lead author of the article and a policy researcher ...
Cached Medicine News:Health News:SCAI and ACC announce new interventional cardiology meeting 2Health News:New HIV diagnoses rising in New York City among young men who have sex with men 2Health News:New HIV diagnoses rising in New York City among young men who have sex with men 3Health News:New HIV diagnoses rising in New York City among young men who have sex with men 4Health News:PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building 2Health News:New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users 2Health News:New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users 3Health News:RAND researchers offer options to improve immigrant health care quality, access 2
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
... EVS has an ergonomic stapler ... mechanism which requires a single ... locks onto the target vessel ... site before, during and after ...
Medicine Products: